AVEO Oncology Announces Participation at the 2021 SVB Leerink Global Healthcare Conference
AVEO Oncology (Nasdaq: AVEO) announced that CEO Michael Bailey will participate in a fireside chat at the 2021 SVB Leerink Global Healthcare Conference on February 25, 2021, at 3:00 p.m. ET. Investors can access a live webcast through the investors section of AVEO's website, with a replay available for 30 days post-event. AVEO focuses on oncology treatments, particularly its lead candidate tivozanib, approved in the EU for advanced renal cell carcinoma (RCC), and is in trials for U.S. regulatory approval. The company is also advancing its pipeline of monoclonal antibodies.
- Michael Bailey's participation at the prominent 2021 SVB Leerink Global Healthcare Conference can enhance company visibility.
- Tivozanib's approval in the EU indicates a successful regulatory pathway and potential revenue streams.
- Ongoing clinical trials for tivozanib in the U.S. could lead to further market opportunities.
- Reliance on regulatory approval for tivozanib's marketing in the U.S. remains a risk factor.
- Potential delays or failures in clinical trials could adversely affect stock performance.
AVEO Oncology (Nasdaq: AVEO) today announced that Michael Bailey, president and chief executive officer of AVEO, will participate in a fireside chat at the 2021 SVB Leerink Global Healthcare Conference on Thursday, February 25, 2021 at 3:00 p.m. Eastern Time.
A live webcast of the fireside chat can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. A replay of the webcast will be archived for 30 days following the presentation date.
About AVEO Pharmaceuticals, Inc.
AVEO is an oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for cancer patients. AVEO’s strategy is to focus its resources toward development and commercialization of its product candidates in North America, while leveraging partnerships to support development and commercialization in other geographies. AVEO’s lead candidate, tivozanib, is approved as FOTIVDA® in the European Union and other countries in the EUSA territory for the treatment of adult patients with advanced RCC. Tivozanib is being studied in the TIVO-3 trial, which is supporting a regulatory submission of tivozanib in the U.S. seeking marketing approval as a treatment for relapsed or refractory RCC. AVEO has previously reported promising early clinical data on ficlatuzumab (anti-HGF mAb) in head and neck cancer, acute myeloid leukemia and pancreatic cancer and is conducting a randomized Phase 2 confirmatory clinical trial of ficlatuzumab in head and neck cancer. AVEO’s earlier-stage pipeline includes several monoclonal antibodies in oncology development, including AV-203 (anti-ErbB3 mAb), AV-380 (anti-GDF15 mAb) and AV-353 (anti-Notch 3 mAb). AVEO is committed to creating an environment of diversity and inclusion as a foundation for innovation.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements of AVEO within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Actual results or events could differ materially due to a number of important factors, including risks discussed in the section titled “Risk Factors” in AVEO’s most recent Annual Report on Form 10-K, its quarterly reports on Form 10-Q and its other filings with the SEC. The forward-looking statements in this press release represent AVEO’s views as of the date of this press release. AVEO anticipates that subsequent events and developments may cause its views to change. While AVEO may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. You should, therefore, not rely on these forward-looking statements as representing AVEO’s views as of any date other than the date of this press release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210218005290/en/
FAQ
When will Michael Bailey speak at the SVB Leerink Global Healthcare Conference?
How can I access the AVEO Oncology fireside chat?
What is AVEO’s lead candidate for cancer treatment?
What are the clinical trials AVEO is currently conducting?
What is the significance of the SVB Leerink Global Healthcare Conference for AVEO?
